Find, compare & contact
Udenafil
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Udenafil API 268203-93-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Udenafil. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Udenafil
- Synonyms:
- Udenafil
- Cas Number:
- 268203-93-6
- DrugBank number:
- DB06267
- Unique Ingredient Identifier:
- L5IB4XLY36
About Udenafil
It's time for some technical information for the ones who understand chemistry: Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.
Ask the supplier for a certificate of analysis to find out more about the quality of Udenafil.
Udenafil is a type of Phosphodiesterase-5 inhibitors
Phosphodiesterase-5 inhibitors are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that are widely used in the treatment of various medical conditions. These inhibitors target the enzyme phosphodiesterase-5, which plays a crucial role in the regulation of cyclic guanosine monophosphate (cGMP) levels in the body.
By inhibiting phosphodiesterase-5, these APIs effectively increase the concentration of cGMP in certain tissues and organs, leading to several beneficial effects. One of the most well-known applications of phosphodiesterase-5 inhibitors is in the treatment of erectile dysfunction (ED). These medications, such as sildenafil, tadalafil, and vardenafil, work by enhancing the blood flow to the penile tissues, promoting and sustaining erections.
Phosphodiesterase-5 inhibitors also find applications in the treatment of pulmonary arterial hypertension (PAH). By dilating the blood vessels in the lungs, these APIs reduce the workload on the heart and improve exercise capacity in PAH patients. Furthermore, they are being explored for their potential benefits in other areas, such as the treatment of Raynaud's disease and altitude sickness.
It is important to note that phosphodiesterase-5 inhibitors should be used under medical supervision, as they can interact with other medications and have potential side effects. Common side effects include headache, flushing, nasal congestion, and gastrointestinal disturbances.
In summary, phosphodiesterase-5 inhibitors are a class of pharmaceutical APIs that are widely utilized for the treatment of erectile dysfunction and pulmonary arterial hypertension. Their ability to selectively inhibit phosphodiesterase-5 and modulate cGMP levels makes them valuable therapeutic agents in managing these conditions.
Udenafil (Phosphodiesterase-5 inhibitors), classified under Genitourinary Agents
Genitourinary agents are a category of pharmaceutical active ingredients (APIs) that are specifically designed to target and treat disorders related to the genitourinary system. The genitourinary system encompasses the organs and structures involved in the production, storage, and elimination of urine, as well as the reproductive organs.
These APIs play a crucial role in the treatment of various genitourinary conditions, including urinary tract infections (UTIs), erectile dysfunction, urinary incontinence, benign prostatic hyperplasia (BPH), and other related disorders. They exert their therapeutic effects by interacting with specific receptors or enzymes in the genitourinary system, regulating physiological processes, and restoring normal function.
Some commonly used genitourinary agents include alpha-blockers, which relax the smooth muscles in the prostate and bladder neck, improving urine flow in patients with BPH. Additionally, phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are widely prescribed for erectile dysfunction, as they enhance blood flow to the penile tissues, facilitating erection.
These APIs are typically formulated into various dosage forms, such as tablets, capsules, creams, gels, or injections, allowing for convenient administration to patients. The development and production of genitourinary agents involve stringent quality control measures and compliance with regulatory guidelines to ensure safety, efficacy, and consistent product performance.
In summary, genitourinary agents form a crucial category of pharmaceutical APIs used to treat a range of disorders affecting the genitourinary system. Their targeted mechanisms of action and diverse dosage forms make them valuable tools in improving genitourinary health and enhancing patients' quality of life.
